2:I[231,["231","static/chunks/231-13cb1b3c6d429521.js","669","static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js"],""]
3:I[9275,[],""]
5:I[1343,[],""]
6:I[8173,["231","static/chunks/231-13cb1b3c6d429521.js","410","static/chunks/410-0180f9689c5eaba7.js","185","static/chunks/app/layout-cc68188960cc2107.js"],"Image"]
4:["ticker","RAD","d"]
0:["UmLDHh5gfJqJU4XymIubn",[[["",{"children":["asx",{"children":[["ticker","RAD","d"],{"children":["__PAGE__?{\"ticker\":\"RAD\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","RAD","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does RAD do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"RAD develops targeted theranostic products (diagnostics and therapies) using radiopharmaceuticals, primarily for cancer treatments.\"}},{\"@type\":\"Question\",\"name\":\"Is RAD a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"RAD offers high growth potential due to its innovative approach, but as a small-cap biotech, it comes with high risk due to clinical trial uncertainties and capital requirements.\"}},{\"@type\":\"Question\",\"name\":\"What drives RAD's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key drivers include clinical trial outcomes, strategic partnerships, regulatory approvals, and the overall biotech sector sentiment on the ASX.\"}}]}"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Radiopharm Theranostics Limited"," (","RAD",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Radiopharm Theranostics Limited (ASX: RAD), listed in November 2021, operates in the Health Care sector focusing on Pharmaceuticals, Biotechnology, and Life Sciences. They are developing targeted theranostic products for cancer treatment, primarily working in Australia with potential for global market expansion. Key products/services include radiopharmaceuticals for both diagnostic imaging and targeted cancer therapy."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$78M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"Price Chart (TradingView)"}],["$","div",null,{"className":"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400","children":["Embed TradingView widget here for ","RAD",". The production version should load live pricing and technical indicators."]}]]}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","As a recent ASX debutant with a market cap of A$78M, RAD is in an early development stage, characteristic of high-risk, high-reward biotech investments. Recent performance may reflect listing adjustments and initial operational setup. Key metrics to watch include R&D expenditure, partnership announcements, and clinical trial timelines.",{"children":"As a recent ASX debutant with a market cap of A$78M, RAD is in an early development stage, characteristic of high-risk, high-reward biotech investments. Recent performance may reflect listing adjustments and initial operational setup. Key metrics to watch include R&D expenditure, partnership announcements, and clinical trial timelines."}],["$","p","Growth prospects hinge on successful clinical trials, strategic partnerships, and regulatory approvals. Upcoming catalysts might include Phase I/II trial results for lead compounds, collaborations with larger pharmaceutical firms, or expansion into new therapeutic areas.",{"children":"Growth prospects hinge on successful clinical trials, strategic partnerships, and regulatory approvals. Upcoming catalysts might include Phase I/II trial results for lead compounds, collaborations with larger pharmaceutical firms, or expansion into new therapeutic areas."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Successful Phase II clinical trial results for a lead radiopharmaceutical candidate, leading to significant partnership interest or valuation boost",{"children":["â€¢ ","Successful Phase II clinical trial results for a lead radiopharmaceutical candidate, leading to significant partnership interest or valuation boost"]}],["$","li","Strategic partnership with a global pharmaceutical company for development and commercialization, providing financial and technical validation",{"children":["â€¢ ","Strategic partnership with a global pharmaceutical company for development and commercialization, providing financial and technical validation"]}],["$","li","Approval for a diagnostic imaging product in a major market (e.g., Australia, US, EU), generating early revenue streams",{"children":["â€¢ ","Approval for a diagnostic imaging product in a major market (e.g., Australia, US, EU), generating early revenue streams"]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Unfavorable results from critical clinical trials, halting development of a key asset and impacting investor confidence",{"children":["â€¢ ","Unfavorable results from critical clinical trials, halting development of a key asset and impacting investor confidence"]}],["$","li","Intense competition from established biotech firms with more advanced theranostic pipelines, limiting RAD's market share potential",{"children":["â€¢ ","Intense competition from established biotech firms with more advanced theranostic pipelines, limiting RAD's market share potential"]}],["$","li","Significant dilution from repeated capital raisings to fund lengthy and costly clinical development phases",{"children":["â€¢ ","Significant dilution from repeated capital raisings to fund lengthy and costly clinical development phases"]}]]}]]}]]}]]}],null,["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Quarterly Activities/Appendix 4C Cash Flow Report"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"27 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Rad Ltd, a commitments test entity on ASX, has reported its quarterly cash flow activities in Appendix 4C of the latest financial documents. Investors should review these details to assess Rad's liquidity and capital allocation strategies for this period."}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"RAD Increases Ownership in Radiopharm Ventures to 87.5%"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"11 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Progress Report"}]]}],""]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Change in substantial holding"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"6 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Substantial Holder"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does RAD do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does RAD do?"}],["$","p",null,{"className":"text-slate-400","children":"RAD develops targeted theranostic products (diagnostics and therapies) using radiopharmaceuticals, primarily for cancer treatments."}]]}],["$","div","Is RAD a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is RAD a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"RAD offers high growth potential due to its innovative approach, but as a small-cap biotech, it comes with high risk due to clinical trial uncertainties and capital requirements."}]]}],["$","div","What drives RAD's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives RAD's share price?"}],["$","p",null,{"className":"text-slate-400","children":"Key drivers include clinical trial outcomes, strategic partnerships, regulatory approvals, and the overall biotech sector sentiment on the ASX."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.02"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-red-400","children":["-18.5","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$78M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"25/11/2021"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L2",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L2",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L2",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$4","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L2",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L6",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L2","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L2","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L2","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L2","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L2","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L2","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 sm:flex","children":[["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden","children":[["$","span",null,{"children":"AI market insights for ASX investors"}],["$","$L2",null,{"href":"/screener","className":"text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L3",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L5",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L2",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L2",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L2",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/115c5e9658b2e8f5.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$L7"]]]]]
7:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"RAD share price, analysis & company profile - Radiopharm Theranostics Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest RAD share price overview, what Radiopharm Theranostics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/RAD/"}],["$","meta","5",{"property":"og:title","content":"RAD share price, analysis & company profile - Radiopharm Theranostics Limited"}],["$","meta","6",{"property":"og:description","content":"Latest RAD share price overview, what Radiopharm Theranostics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/RAD/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"RAD share price, analysis & company profile - Radiopharm Theranostics Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest RAD share price overview, what Radiopharm Theranostics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
